Topics

Stem Holdings, Inc. Taps Former Hain Celestial Group, Executive as Executive Vice President & Chief Operating Officer to Drive Strategic Growth Initiatives

08:00 EDT 3 Oct 2019 | Businesswire
Stem Holdings, Inc.
  •  Ellen B. Deutsch is a 20-year business veteran and former Chief Growth Officer and Chief Marketing Officer at The Hain Celestial Group, Inc. (Nasdaq: HAIN)
  • Ms. Deutsch will spearhead operations, strategic development, and market leadership following a series of recent acquisition and partnership announcements

Stem Holdings, Inc. (OTCQX: STMH CSE: STEM), (the “Company” or “Stem”), a leading vertically-integrated cannabis company with state-of-the-art cultivation, processing, extraction, distribution, and retail, and operations, is pleased to announce the appointment of Ellen B. Deutsch as Executive Vice President and Chief Operating Officer. Ms. Deutsch will oversee all the operations for driving revenue and efficiency across all of its various business segments including cultivation, production, distribution and retail.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191003005223/en/

(Photo: Business Wire)

(Photo: Business Wire)

Ms. Deutsch brings to Stem more than 20 years of senior leadership experience where she was most recently a Senior Vice President and Chief Marketing Officer at The Hain Celestial Group, Inc. (Nasdaq: HAIN), a leading natural and organic food and personal care products company in North America, Europe, and India. During her more than 20 years at Hain, Ms. Deutsch also held a variety of senior leadership executive roles, including SVP/Global Technical Services and Chief Sustainability Officer, and SVP/Strategic Planning and Customer Satisfaction, and SVP/Global Marketing and Sales, during which time she led numerous business teams and functional areas, identified and integrated acquisitions, and created the Company’s technical and corporate social responsibility platforms. Ms. Deutsch holds both her BBA and MBA degrees from Hofstra University’s Frank G. Zarb School of Business.

“We are delighted to welcome Ellen to Stem Holdings,” said Mr. Adam Berk, Chief Executive Officer of Stem. “She possesses extensive leadership experience, multi-dimensional skills, and a proven track-record of execution in delivering profitable growth. She is a great addition to the team, and we look forward to leveraging her expertise at a time where we are growing and becoming a truly vertically integrated Company in one of the largest emerging industries. Our focus will be to continue to execute our business plan and drive continued strategic growth and shareholder value.”

“Given the Company’s commitment to innovation, quality, and compliance, I believe Stem is well poised for strong growth across all channels, markets, and verticals,” said Ms. Deutsch. “I feel honored to begin working with a great team of experts and dedicated professionals as we enter into the next phase of our corporate trajectory.”

ABOUT STEM HOLDINGS, INC.

As a vertically-integrated cannabis company, Stem is as a pioneer in the industry with its state-of-the-art cultivation, processing, extraction, retail, and distribution operations. Stem owns cannabis facilities in California, Nevada, Oklahoma, and Oregon and hemp facilities in Pennsylvania and New York and also participates in a research project in collaboration with Cornell University. Utilizing proprietary, sustainable cultivation techniques, Stem develops exceptional products that are safe and consist of lab-tested cannabis and CBD. Stem’s owned and partner consumer brands are award-winning and nationally known including cultivators TJ's Gardens® and Yerba Buena®; retail banners Stem and TJ's; infused product manufacturers, CannavoreTM and Supernatural HoneyTM; and a new CBD company, Dose-ologyTM. Stem's mission in supporting the health and happiness of people and the safety of our planet is evident through the Company's continued recognition for its community involvement, employee diversification, and as a top place to work in cannabis, as well as dedication to environmental causes and outstanding leadership in the cannabis industry.

Cautionary Note Regarding Forward-Looking Information

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the management of Stem with respect to future business activities. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and include information regarding: (i) the ability of the Company to successfully achieve its business objectives, (ii) plans for expansion of Stem, (iii) expectations for other economic, business, and/or competitive factors, and (iv) anticipated growth.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflect the management of Stem’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Stem believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Company operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws, including those related to taxation; the inability to locate and acquire suitable companies, properties and assets necessary to execute on the Company’s business plans; and increasing costs of compliance with extensive government regulation. This forward-looking information may be affected by risks and uncertainties in the business of Stem and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Stem has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Stem does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

No securities regulatory authority has in any way passed upon the merits of the proposed transactions described in this news release or has approved or disapproved of the contents of this news release.

Media:
Mauria Betts
Director of Branding and Public Relations
(971) 266-1908
mauria@stemholdings.com

Investor Relations:
John Mills
ICR, LLC
(646) 277-1254
john.mills@ICRinc.com

NEXT ARTICLE

More From BioPortfolio on "Stem Holdings, Inc. Taps Former Hain Celestial Group, Executive as Executive Vice President & Chief Operating Officer to Drive Strategic Growth Initiatives "

Quick Search

Relevant Topics

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...